GlassScriptPhysician profile
Rima Bakhda
NPI 1750793444
$1,760.25
in general payments reported to CMS, 2019-2025
24 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $268 · 2021: $267 · 2022: $187 · 2023: $417 · 2024: $311 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $346.66 | 2022-2024 | Ubrelvy, Qulipta, Vraylar |
| Neurocrine Biosciences, INC. | $165.63 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $161.47 | 2020-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $140.68 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $130.65 | 2020-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $112.39 | 2022-2025 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $84.58 | 2024-2025 | Trintellix |
| Lundbeck LLC | $78.68 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.77 | 2021-2025 | Caplyta |
| Eisai INC. | $63.83 | 2020 | |
| Alkermes, INC. | $60.72 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $56.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.30 | 2024 | Invega, Spravato |
| Lilly USA, LLC | $39.91 | 2025 | Zepbound, Mounjaro, Kisunla |
| Dexcom, INC. | $36.98 | 2023 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $32.09 | 2021 | |
| Abbott Laboratories | $24.95 | 2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $20.31 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $19.68 | 2022 | |
| Noven Therapeutics, LLC | $17.00 | 2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $16.41 | 2021 | |
| Exact Sciences Corporation | $16.38 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rima Bakhda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.